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Objective: Appropriate tuberculosis (TB) treatment guidelines are one of the many factors that influence the success of TB treatment. The patient’s 
drug supervisor is a functional role that is part of the directly observed treatment short course, a program to support the success of TB treatment. 
The aim of this study was to analyze the TB treatment suitability in a community health center and the benefit of treatment compliance supervision 
by the patient’s designated drug supervisor.
Methods: We conducted a cross-sectional study in the Community Health Center of Pademangan subdistrict, North Jakarta, involving 205 subjects to 
analyze appropriate fixed-dose combination (FDC) anti-TB drug administration and an experimental study involving 23 control group TB patients and 
23 intervention group TB patients to assess the benefit of supervision by each patient’s drug supervisor.
Results: The association of FDC anti-TB drug side effects with the success of TB treatment was not statistically significant (p=0.173). There was 
an increase in drug supervisor knowledge of 8.6% in the intervention group and 13% in the control group. There was no statistically significant 
association between the knowledge of the drug supervisor and the 2nd month (p=0.575) and the 6th month of sputum treatment.
Conclusion: Minor side effects of FDC anti-TB drug did not affect the success of TB treatment; therefore, treatment was continued if these adverse 
events occurred. There were no correlations between the drug supervisor knowledge level with medication compliance or with sputum conversion 
(months 2 and 6).
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INTRODUCTION
Tuberculosis (TB) is a contagious infectious disease that receives 
great attention worldwide because it has the highest mortality rate 
in the world [1,2]. The disease is caused by bacterial infection of 
Mycobacterium TB that is transmitted through the air. In 2014, 9 million 
people were infected with TB each year worldwide, 1.5 million people 
died of TB, and >3 million people with TB were undiagnosed or treated. 
On average, every person with undiagnosed TB infects 15 people each 
year.
An appropriate TB treatment guide is one of the factors that influence 
the success of TB treatment. Several factors should be taken into 
consideration, such as the characteristics of the bacteria or acid-
resistant bacilli (BTA) itself, the clinical characteristics of patients 
with heterogeneity, patient behavior or attitudes, quality of health 
care, presence or absence of TB coinfection-human immunodeficiency 
virus (TB-HIV), anti-TB drug (anti-TB drug) side effects, delayed 
administration of anti-TB drug, and multidrug-resistant TB 
(MDR-TB) [3]. These factors can be assessed and traced to evaluate 
the success of TB treatment because direct supervision is required to 
determine the attitudes and behaviors of real patients.
According to the World Health Organization, a drug use study (DUS) 
is one that covers the marketing, distribution, and prescribing and 
use of medicines in the community by considering the patient’s 
clinical and socioeconomic consequences. Pharmacovigilance 
involves the monitoring, evaluation, and prevention of adverse effects, 
especially long-term and short-term side effects, associated with the 
administration of medicines. DUS and pharmacovigilance are parts of 
pharmacoepidemiology [4].
Treatment of TB patients using fixed-dose combination (FDC) drugs has 
not been able to eradicate 100% of TB in patients in Indonesia, which 
still has the second highest prevalence of TB patients in the world. The 
number of cases of the pulmonary TB in DKI Jakarta Province in 2012 
was 24,500 [5]. It is estimated that every year, 253 new TB cases are 
found, of which about one-third of patients are located around the 
Community Health Center, Pademangan subdistrict, North Jakarta [6].
The aim of the present study was to assess the suitability of FDC TB 
treatment and the role of the drug supervisor (a designated person who 
helps ensure a patient’s treatment compliance) in a Community Health 
Center in North Jakarta, Indonesia. Please note that the drug supervisor 
is a part of the directly observed treatment short course, which is a 
program designed to support the successful treatment of TB patients.
METHODS
We conducted a cross-sectional study to determine the suitability of TB 
treatment at a Community Health Center by reviewing medical records’ 
data and TB-01 card from 2012 to 2014. In addition, we conducted an 
experimental study in which we provided counseling and training to 
one group of drug supervisors and none to another group as the control. 
The drug supervisors were randomly assigned to the intervention and 
control groups. Drug supervisors are often family members who may 
live with the TB patient.
For research purposes 1–4, the study was conducted at the Community 
Health Center of Pademangan subdistrict, North Jakarta. For research 
purposes 5–8, the study was conducted at the Community Health Center 
of Pademangan subdistrict, North Jakarta, and at the Community Health 
Center of East Pademangan, North Jakarta. The study was conducted from 
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January 2015 to December 2015. For research purposes 1–4, the study 
group comprised all the TB patients, and for research purposes 5–8, the 
study group comprised TB patients supervised by drug supervisors.
The study sample was taken from a population that met the following 
inclusion criteria and did not meet the exclusion criteria. For the 
research purposes 1–4, the inclusion criteria were pulmonary 
and extrapulmonary TB patients, age ≥17 years, and the exclusion 
criteria were patients with MDR-TB, TB-HIV, or were pregnant and 
had incomplete or unreadable medical records’ data. For research 
purposes 5–8, the inclusion criteria were drug supervisor patients with 
new pulmonary TB or treatment of <1 month with positive smears 
or negative smears, but a positive radiological examination, drug 
supervisor patients with pulmonary TB, age 17–65 years old, and were 
willing to sign informed consent, and the exclusion criteria were drug 
supervisor pulmonary TB patients in Category II anti-TB drug, drug 
supervisor MDR-TB patients, and drug supervisor pregnant TB patients.
For research purposes 1–4, all the data (medical records and TB-01 
cards TB patients starting from 2012 to 2014) were sampled. For the 
research purposes 5–8, consecutive sampling was used. The subjects 
were randomly selected for placement in intervention or control groups. 
For research purposes 1–4, the approximate sample size was calculated 
using a single large sample formula to estimate the proportion of a 
population according to the following equation:
n=Zα2PQ/d2 with Zα=95%
For research purposes 5–8, the approximate sample size was calculated 
using a single large sample formula to estimate the proportion of a 
population according to the following equation:
n1=n2=(Zα √2PQ+Zβ √(P1Q1 + P2Q2))2/(P1−P2) 2,
With Zα=95% and a power hypothesis of 80%.
All the patient data were kept confidential in accordance with the 
research code of conduct. Approval of the research protocol was 
obtained from the (1) research ethics committee of the Faculty of 
Medicine, University of Indonesia, (2) subdepartment of the city health 
administration of North Jakarta, and (3) Head of Community Health 
Center Subdistrict of Pademangan North Jakarta.
Data collection was performed from medical records and TB-01 cards 
from 2012 to 2014. Data collection was also performed through 
questionnaires given and filled by the drug supervisor (direct 
interview) before and after training in both research groups. The first 
questionnaire (pretest) was given when the drug supervisor began 
treatment of the patient and after receiving counseling from TB officers 
in the Community Health Center. After the pre-test, the research 
subjects (drug supervisors) belonging to the intervention group 
received counseling from researchers on basic TB knowledge and drug 
supervisor duties; however, the control group did not. 1 week later, after 
pre-test replenishment, the researcher gave the second questionnaire 
(post-test) with the same question to both of the groups (control 
group and intervention group). Knowledge of the drug supervisor was 
considered sufficient for a score ≥8 of 10 questions, with the score 
including questions 3, 5, and 6.
Statistical analysis
All the research data were recorded in a manual and an electronic form. 
Descriptive and analytical statistical analyses were performed. The 
intention to treat method was used to analyze the data. The statistical 
system used was SPSS 22.0 software.
RESULTS
For research purposes 1–4, the data collection of this research was 
performed using the TB patient’s medical records and TB-01 cards, 
with the data collected from the 205 subjects who fulfilled the inclusion 
criteria. The data were collected in the subdistrict of Pademangan, 
North Jakarta, from 2012 to 2014.
Descriptive analysis of the 205 study subjects’ demographic 
characteristics was performed. The characteristics included sex, age, 
weight, type of TB, medication status, weight gain, and comorbidities 
(Table 1). The frequency distribution analysis of the data included 
the number of patients receiving FDC, accuracy of the FDC category, 
accuracy of the FDC indication, accuracy of the duration of FDC 
administration, accuracy of FDC dosage, presence/absence of side 
effects, frequency of smear examination before treatment, proportion 
of conversion BTA after 2 months and 6 months of treatment, and the 
presence or absence of a drug supervisor (Table 2).
Among the 205 subjects in this study, 197 (96.1%) patients were in 
the FDC Category 1 and 8 (3.9%) patients were in the FDC Category 
2. 10 (5.1%) patients received FDC Category 1 insertion and no (0%) 
patients received Category 2 insertion.
p=0.173 was obtained (Fisher’s test). p>0.05 result indicated that there 
was no significant relationship between the side effects and treatment 
success, with a prevalence ratio of 0.757 (95% IK: 0.077–1.612).
For research purposes 5–8, a descriptive analysis of the demographic 
characteristics of the 46 TB patients in the experimental study was 
performed. The demographic characteristics included sex, age, 
educational level, occupation, and marital status (Table 3).
In the experimental study, 6 (26.1%) of the 23 subjects had sufficient 
knowledge in the control group on the pre-test. 3 (13.1%) of the 23 
subjects had sufficient knowledge in the intervention group on the 
pre-test. 9 (39.1%) of the 23 subjects had sufficient knowledge in 
the control group on the post-test. 5 (21.7%) of the 23 subjects had 
sufficient knowledge in the intervention group on the post-test.
Table 1: Demographic characteristics










55–70 kg 44 21.5
≥71 kg 7 (3.4)
4. TB type
Lung TB paru 202 (98.5)
Extra lung TB 3 (1.5)
5. TB medication status
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In the intervention group, there was an increase in the percentage of 
drug supervisors with sufficient knowledge, from 13.1% to 21.7% 
(increase of 8.6%); however, the control group also increased from 
26.1% to 39.1% (increase of 13%).
Compliance with treatment for 6 months was 100% among the patients 
supervised by the 46 research subjects (drug supervisors). There 
was no correlation between drug supervisor knowledge and patient 
compliance with TB treatment for 6 months (the null hypothesis was 
correct). The number of drug supervisors with adequate knowledge of 
medication was 14 (30.4%), and 32 (69.6%) did not.
There was 100% successful sputum conversion after 6 months among 
the 46 research subjects. There was no significant correlation between 
the knowledge of the drug supervisor and sputum conversion after 
6 months of treatment (null hypothesis was true). However, the number 
of drug supervisors with sufficient knowledge of successful conversion 
was 14 (30.4%) and 32 (69.6%) for those without sufficient knowledge.
There was 100% compliance with TB treatment among the 46 research 
subjects. There was no correlation between TB treatment for 6 months 
and sputum conversion after 2 months of treatment. The number of 
patients who adhered to successful treatment of sputum after 2 months 
was 44 (95.6%), and 2 (4.4%) did not.
There was no significant correlation between TB treatments for 
6 months of sputum conversion. The number of patients who adhered 
to successful treatment sputum after 6 months of treatment was 
46 (100%), and there were no (0%) unsuccessful conversions.
DISCUSSION
In the assessment of the suitability of FDC administration, 198 (96.6%) 
TB patients were in accordance with the indication of FDC 
administration, whereas 7 (3.4%) were not. The proper indications for 
FDC administration were patients who had been diagnosed as having 
TB (clinical symptoms and investigation) and were suitable for FDC 
anti-TB drug treatment, and improper indications were patients who 
tested sputum smear negative (−), had no lung radiology examination, 
but had already been given FDC anti-TB drugs. This is not appropriate 
because TB drug delivery should be given to patients who have been 
diagnosed as having TB through clinical symptoms and investigations 
that have been established.
Based on the accuracy of the duration of FDC, it was found that 
141 (74.2%) subjects were correctly indicated; however, 49 (25.8%) were 
inappropriate subjects. The duration of FDC depended on the type of TB 
suffered, namely pulmonary TB (6 months) or extra lung (depending on 
the type of TB). The duration of FDC administration also depended on 
comorbidities of the TB patients (e.g., TB patients with Type 2 diabetes 
mellitus were treated for 9 months). The inaccuracy of the duration of 
FDC administration in this study was due to FDC in lung TB patients given 
for only 5 months instead of the required 6 months, FDC administration 
in TB patients with type 2 diabetes that was not given for 9 months (TB 
infection could trigger increased variability in blood sugar), and patients 
with TB lymphadenitis who were not treated for 9 months.
For accurate delivery of FDC dosage, the dosage of FDC Category 1 
was appropriate for 175 (85.4%) subjects and that of FDC category 2 
was appropriate for 4 subjects (1.9%). Inappropriately administered 
doses were given to 26 patients (FDC Category 1 for 24 patients, 2 for 
2 patients, and 0% FDC insertion). Inaccurate doses occurred due to 
improperly assigned FDC doses and injection of streptomycin for early 
weight treatment; the dosage of FDC and injection of streptomycin 
Table 2: Frequency distribution of the data based on research 
variables
No. Variable Frequency n (%)
1. Number of patients receiving FDC
Cat 1 199 (97.1)
Cat 2 6 (2.9)
Inflix cat 1 10 (5.1)
Infilix cat 2 0 (0)
2. Accuracy of category FDC granting
Accurate 205 (100)
Not accurate 0 (0)
3. Accuracy of indication of FDC granting
Accurate 198 (96.6)
Not accurate 7 (3.4)
4. Accuracy of the duration of FDC
Accurate 141 (74.2)
5. Accuracy of FDC dosing side effects apparent
Not accurate 49 (25.8)
Accurate 176 (85.9)
6. BTA examination before medication
Not accurate 29 (14.1)
7. BTA sputum conversion
*After 2 months of medication
Yes 13 (6.3)
No 192 (93.7)










Table 3: Demographic characteristics data 





Man 5 (21.7) 7 (30.4)
Woman 18 (78.3) 16 (69.6)
Age (years) 
<30 5 (21.7) 5 (21.7)
30–49 12 (52.2) 11 (47.9)
>49 6 (26.1) 7 (30.4)
Education status
Elementary 5 (21.7) 14 (60.9)
Junior high 5 (21.7) 4 (17.4)
Senior high 10 (43.5) 4 (17.4)
High 3 (13.1) 1 (4.3)
Job
Employed 13 (56.5) 9 (39.1)
Unemployed 10 (43.5) 14 (60.9)
Marital status
Married 19 (82.6) 19 (82.6)
Single 4 (17.4) 4 (17.4)
BTA sputum conversion
*After 2 months of medication
Conversion (+) 22 (95.6) 22 (95.6)
Conversion (−) 1 (4.4) 1 (4.4)
*After 6 months of medication
Conversion (+) 23 (100) 23 (100)
Conversion (−) 0 (0) 0 (0)
Relationship between drug 
supervisor and patient
Husband/wife 5 (21.7) 8 (34.8)
Children 4 (17.4) 3 (13.1)
Parents 1 (4.3) 10 (43.5)
Siblings 8 (34.8) 1 (4.3)
Others 5 (21.7) 1 (4.3)
There  was  no  significant  correlation  between  knowledge  of  the 
drug supervisor and sputum TB patients after 2 months of
 treatment  (p=0.575,  Fisher’s  exact  test;  odds  ratio  1  061  [95%  IK: 
0.978–1.151]).
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did not follow by any weight gain. At this Community Health Center, 
streptomycin was given at a dose of 750 mg for all patients’ body 
weights, which is incorrect because if a patient has weight gain, the 
dose of FDC and streptomycin should also be adjusted [7,8].
A study by Giri (2013) conducted at a health center in Surakarta with 
a total sample of 130 samples showed that the accuracy of FDC anti-
TB drug indication was 100%, whereas the accuracy in our study 
was 96.6%. This result was probably due to the larger sample used to 
increase the strength of the study. There were still 3.4% inappropriate 
indications for anti-TB drug FDC because seven patients were AFB 
(−), had no chest radiological examination, but received FDC anti-TB 
drug therapy. The accuracy of the given category, both in Giri’s study 
(2013) and in this study, was 100%. For the accuracy of dosing, Giri’s 
study had a higher inaccuracy percentage (17.7%) than in our study 
(14.1%). In our study, the inaccuracy of the anti-TB drug FDC dosage 
was not caused by ignorance or neglect of the TB drug supervisor in 
the Community Health Center. The TB drug workers said that they were 
afraid of insufficient FDC anti-TB drug availability because each TB 
patient was given a box of FDC anti-TB drug. For the duration of FDC 
anti-TB drug in this study, there were still doubts among the TB officials 
about the duration of administration, especially in extrapulmonary TB 
patients and comorbid TB (e.g., type 2 diabetes mellitus); however, 
they rarely consulted with doctors to practice there because too many 
patients were treated at the Community Health Center, where medical 
personnel, places, and time are limited.
The inaccuracies in the duration of administration and the dose 
administered to the subjects of this study may lead to FDC anti-TB drug 
resistance, which means that patients will tend to fall into the MDR-
TB state in addition to the possibility of genetic polymorphism and 
transmission from other MDR-TB patients. It is important to avoid this 
because long-term treatment of MDR-TB and many unwanted effects of 
drugs can arise.
The patient side effects that were seen in this study were minor. In 
the event of major side effects, the patient was immediately referred 
to the nearest referral hospital. Research conducted by Samsu (2010) 
showed that among 168 study subjects, 23.2% experienced side 
effects [9]. In our study, side effects occurred only in 6.3% of patients 
and included heartburn (3.4%), nausea (2.4%), vomiting (1%), joint 
pain (1%), rash (0.5%), and headache 0.5%. Heartburn, nausea, and 
vomiting are usually caused by pyrazinamide anti-TB drugs, rifampicin, 
and isoniazid. Joint pain and headache are caused by rifampicin. Rash 
is caused by streptomycin, isoniazid, rifampicin, and pyrazinamide. 
However, because FDC is a combination of anti-TB drugs, it is difficult to 
determine with certainty the anti-TB drug that causes these side effects. 
There is no guidance on the management of these minor side effects at 
the Community Health Center, so management varies.
The results of this study showed that successful conversion increased 
from 71.2% to 81.1%. Conversion failed due to inaccurate FDC 
dosage, inaccurate duration of FDC administration, or possibly due to 
pharmacogenetic effects. Further, research is needed in this area.
Among the 205 study subjects, 162 (79%) had a drug supervisor and 
43 (21%) did not. However, because it cannot be seen in the secondary 
data, we could not assess the relationship between the drug supervisor 
and the TB patient. TB patients who do not have a drug supervisor tend 
to be self-assured. In addition, some TB patients live alone; therefore, a 
drug supervisor cannot be assigned.
In this study, 95.6% (control group) and 95.6% (interrupted drug 
supervisor group) of the TB patients had successful BTA sputum smears 
at 2 months of treatment, whereas 4.4% (control group) and 4.4% 
(intervention drug supervisor group) of the patients had unsuccessful 
conversion of BTA sputum. The cause of the failure of conversion is still 
unknown because the patient admitted taking regular medication and 
never missed it. Our policy is that if after FDC insertion for 1 month, the 
patient is still experiencing failure conversion; then, the patient will be 
given FDC Category II. At 6 months of treatment, data obtained from all 
TB patients showed a 100% success rate.
Analysis of the relationship between TB patients and their drug supervisors 
showed that the order of importance in the various relationships of the 
TB patients in the control group was brother/sister, husband/wife, other 
relatives, children, and then father/mother, whereas in the intervention 
group, the order of importance was father/mother, husband/wife, 
children, brother/sister, and other relatives. It is important to understand 
the relationship of TB patients with drug supervisors because if the drug 
supervisor is living with the TB patient, the task of directly monitoring the 
TB patient’s compliance with taking regular medication becomes easier.
Among the 46 TB patients in the experimental study on the role of 
drug supervisors, 100% achieved compliance with pulmonary TB 
treatment for 6 months. Therefore, this study showed that there was 
no correlation between the knowledge level of the drug supervisor and 
patient compliance with pulmonary TB treatment for 6 months.
For research purposes 5–8, this study was only conducted in one 
District Community Health Center and three sub-district Community 
Health Centers in the North Jakarta area due to the limited time for this 
research. If extended to Community Health Centers throughout DKI 
with randomization, greater diversity among patients can be achieved 
to more accurately assess treatment suitability and compliance for 
6 months.
CONCLUSION
Minor side effects of FDC anti-TB drugs did not affect the success of TB 
treatment; therefore, treatment was continued despite adverse events. 
There were no correlations between the knowledge level of the drug 
supervisor and medication compliance, sputum conversion (months 
2 and 6), and treatment compliance with sputum conversion (months 
2 and 6). At this Community Health Center, 100% compliance with 
treatment for 6 months was achieved.
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Fig. 1: The frequency distributions of correct answers and wrong 
answers to each question on the post-test questionnaire in the 
control group
Fig. 2: The frequency distributions of correct answers and wrong 
answers to each question on the post-test questionnaire in the 
intervention group
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